Literature DB >> 10553041

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

J Shimizu1, S Yamazaki, S Sakaguchi.   

Abstract

This study shows that removal of a T cell subpopulation can evoke effective tumor immunity in otherwise nonresponding animals. Elimination of CD25-expressing T cells, which constitute 5-10% of peripheral CD4+ T cells in normal naive mice, elicited potent immune responses to syngeneic tumors in vivo and eradicated them. The responses were mediated by tumor-specific CD8+ CTLs and tumor-nonspecific CD4-8- cytotoxic cells akin to NK cells. Furthermore, in vitro culture of CD25+4+ T cell-depleted splenic cell suspensions prepared from tumor-unsensitized normal mice led to spontaneous generation of similar CD4-8- cytotoxic cells capable of killing a broad spectrum of tumors; reconstitution of CD25+4+ T cells inhibited the generation. In this culture, self-reactive CD25-4+ T cells responding to self peptides/class II MHC complexes on APCs spontaneously proliferated upon removal of CD25+4+ T cells, secreting large amounts of IL-2. The IL-2 thus produced appeared to be responsible for the generation of CD4-8- NK cells as lymphokine-activated killer cells, because direct addition of an equivalent amount of IL-2 to the culture of CD4-8- cells generated similar lymphokine-activated killer/NK cells, whereas coculture of normal CD4-8- cells with CD25-4+ T cells from IL-2-deficient mice did not. Thus, removal of immunoregulatory CD25+4+ T cells can abrogate immunological unresponsiveness to syngeneic tumors in vivo and in vitro, leading to spontaneous development of tumor-specific effector cells as well as tumor-nonspecific ones. This novel way of evoking tumor immunity would help to devise effective immunotherapy for cancer in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553041

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  424 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

Review 2.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

3.  In vivo maintenance of T-lymphocyte unresponsiveness induced by thymic medullary epithelium requires antigen presentation by radioresistant cells.

Authors:  Denis Hudrisier; Sonia Feau; Véronique Bonnet; Paola Romagnoli; Joost P M Van Meerwijk
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

Review 4.  Regulation of tumour immunity by CD25+ T cells.

Authors:  Awen Gallimore; Shimon Sakaguchi
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 5.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 6.  The concept of space and competition in immune regulation.

Authors:  Brigitta Stockinger; Thomas Barthlott; George Kassiotis
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

7.  Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes.

Authors:  Olivier Joffre; Nathalie Gorsse; Paola Romagnoli; Denis Hudrisier; Joost P M van Meerwijk
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

8.  Reduction of retrovirus-induced immunosuppression by in vivo modulation of T cells during acute infection.

Authors:  Hong He; Ronald J Messer; Shimon Sakaguchi; Guojun Yang; Shelly J Robertson; Kim J Hasenkrug
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 9.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

10.  Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

Authors:  Adam D Cohen; Adi Diab; Miguel-Angel Perales; Jedd D Wolchok; Gabrielle Rizzuto; Taha Merghoub; Deonka Huggins; Cailian Liu; Mary Jo Turk; Nicholas P Restifo; Shimon Sakaguchi; Alan N Houghton
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.